Another project by Deep Patterns LLC has successfully passed the Skolkovo foundation expertise. This time the project named “DP4SAR – innovative tool for discovering patterns in chemical structures and structure - activity relationships for directed drug design...
OncoMax presented its research results at the 5 th European Multidisciplinary Meeting on Urological Cancers (EMUC) which was held in Marseille, France on 15-17 November 2013. Dr. Ilya Tsimafeyev, Scientific Advisor of Oncomax, won the First Prize for...
Preclinical efficacy study results for the first Russian humanised monoclonal antibody OM-RCA-01, indicated for treatment of renal cell carcinoma, were presented at the New Technologies session of the Congress of the American Society of Clinical Oncology (ASCO...
Adaptive design is an innovative approach that allows to conduct clinical trials more efficiently (with fewer patients, in shorter terms) or to increase the likelihood of demonstrating the effect of the drug. In studies with adaptation, the possibility of modifying...
The aim of the new addendum is introducing improved and more effective approaches to design development, clinical trials, monitoring of their progress, documentation and reporting, and standards for the maintenance of electronic documentation and mandatory...
In December 2012 the modular laser system stLase (represented in the global market under the brand name Alta®) developed within close partnership between Photonics, a portfolio company of Maxwell Biotech Venture Fund and RVC Seed Fund, and the US company...
Hepatera, a Russian biotech company founded in late 2011 with the goal to develop and launch into the Russian market innovative products for treatment of liver diseases, has recently received notification from the Russian Ministry of Health for approval to...
Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative...
SQ109 will be evaluated for efficacy on multi-drug resistant patients Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, licensed the late-stage development and commercialization...
Hepatera, a Russian biotech company and part of Maxwell Biotech Venture Fund's portfolio, has announced today the inclusion of the first three patients with chronic hepatitis B in the clinical trial phase Ib-IIa of Myrcludex B. Hepatera was founded in 2011...
On June 29, the Federal Service on Intellectual Property Rospatent published a list of 100 best inventions in Russia in 2011, which included patent No. 2435783 “Chimeric peptide and it’s pharmaceutical composition for cancer disease treatment”...
Today, April 4th, Maxwell Biotech Venture Fund (MBVF), founded with the participation of RVC, and High-Tech Gründerfonds (HTGF), one of Europe’s largest venture funds, signed a Letter of Intent between the two funds during a joint press conference...
Maxwell Biotech Venture Fund (MBVF), founded with the help of Russian government-backed RVC, announced today that its investment committee approved the terms and the amount of an investment in Eleventa, a Russian biotech company, which was founded earlier in...
Hepatera Ltd. announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund formed with the participation...
On March 23 Julia Trakhtenberg, IPHARMA Medical Director, reported in VIII Scientific-Practical conference on the "Actual tasks of drugs safety evaluation" with the report "Data collection and safety evaluation planning. Clinical trials in diabetology"...
Российская Федерации и Республика Индия давно ведут собственные проекты по внедрению и эксплуатации телемедицинских систем. Особенно активизировались эти работы в последние годы, когда Правительства обеих стран стали уделять серьезное внимание переходу к цифровому...
The second annual awarding ceremony of Investor Awards 2012 winners took place on May 23 in Moscow after the end of the forum Invest in Russia. The investment round in the innovative biotechnological company OncoMax, that received investments from Maxwell Biotech...
On August 18th, 2017, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase IV clinical study of the medicinal product Alflutop®. Protocol № OA-ALF-01 «An open-label multicenter randomized clinical...
Since March 27th to April 26th Skolkovo Biotechnology and Medical Cluster, Skolkovo Open University and fundamental medicine faculty hold the educational program “Pharma’s Cool 2017” . The program include innovative and technical experience...
On October, 30 IPHARMA received the Ministry of Health permission to conduct Phase I trial of Hondrolux®. Protocol № ОА-CLX-01 “Double-blind, randomized, placebo-controlled study to access safety and tolerability of single and following multiple...
On June 22, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase III clinical study of the medicinal product Levopront® (levodropropizine). Protocol № LDP0114 «Multicenter open-label randomized...
On November 17-18, the IV international “Life Sciences Invest. Partnering Russia” partnering forum will be held at Talion Imperial Hotel, Saint Petersburg. Prof. Vyacheslav Duke, founder and scientific director of Deep Patterns, LLC, became a member of the...
The XIV international conference “Regional Informatics-2014” will be held on 29-31 of October in Saint-Petersburg. V. Duke, Deep Patterns founder and scientific director will attend the conference as head of “Information technologies in Health Care industry...